<DOC>
	<DOCNO>NCT02760277</DOCNO>
	<brief_summary>The main purpose study see safe use new medication call vamorolone two week child Duchenne muscular dystrophy ( DMD ) , see vamorolone work treatment DMD , see potential side effect compare see boy use steroid .</brief_summary>
	<brief_title>An Extension Study Assess Vamorolone Boys With Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>This study evaluate safe use new medication call vamorolone two week child DMD , boys DMD take study medication improve muscle function compare boy DMD study take type steroid , see boys DMD take study medication gain less weight compare boy DMD prior study take another type steroid call prednisone . Enrolled participant take study medication 24 week .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Participant 's parent legal guardian provide write informed consent/HIPAA authorization prior extension studyspecific procedure ; 2 . Participant previously complete study VBP15002 include Week 4 Followup assessment within 8 week prior enrollment ; 3 . Participant parent/guardian willing able comply schedule visit , study drug administration plan , study procedure . 1 . Participant serious severe adverse event study VBP15002 , opinion Investigator , probably definitely related vamorolone use precludes safe use vamorolone subject study ; 2 . Participant current history major renal hepatic impairment , diabetes mellitus immunosuppression ; 3 . Participant current history chronic systemic fungal viral infection ; 4 . Participant use mineralocorticoid receptor agent , spironolactone , eplerenone , canrenone ( canrenoate potassium ) , prorenone ( prorenoate potassium ) , mexrenone ( mexrenoate potassium ) within 4 week prior first dose study medication ; 5 . Participant evidence symptomatic cardiomyopathy . [ Note : Asymptomatic cardiac abnormality investigation would exclusionary ] ; 6 . Participant currently treat receive previous treatment oral glucocorticoid immunosuppressive agent . [ Notes : Past transient use oral glucocorticoid oral immunosuppressive agent longer 3 month cumulative , last use least 3 month prior first dose study medication , consider eligibility casebycase basis . Inhaled and/or topical corticosteroid prescribe indication DMD permit must administer stable dose least 3 month prior study drug administration ] ; 7 . Subject use idebenone within 4 week prior first dose study medication ; 8 . Participant allergy hypersensitivity study medication constituent ; 9 . Participant severe behavioral cognitive problem preclude participation study , opinion Investigator ; 10 . Participant previous ongoing medical condition , medical history , physical finding laboratory abnormality could affect safety , make unlikely treatment followup correctly complete impair assessment study result , opinion Investigator ; 11 . Participant currently take investigational drug , take investigational drug vamorolone within 3 month prior start study treatment . Note : Participants may reevaluate ineligible due transient condition would prevent subject participate</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>vamorolone</keyword>
</DOC>